• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

那些杀不死你的，会使你变得更强大：通过细胞骨架重塑和肌球蛋白II重新激活在抗癌治疗中存活下来。

What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation.

作者信息

Orgaz Jose L, Sanz-Moreno Victoria

机构信息

Barts Cancer Institute, Queen Mary University of London, John Vane Science Building, London, UK.

Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Madrid, Spain.

出版信息

Mol Cell Oncol. 2020 Mar 26;7(3):1735911. doi: 10.1080/23723556.2020.1735911. eCollection 2020.

DOI:10.1080/23723556.2020.1735911
PMID:32391428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7199747/
Abstract

Myosin II and its regulator Rho-associated coiled-coil containing protein kinase (ROCK) are essential for cell invasion and metastatic dissemination. Our recent findings show that this molecular machinery is also involved in drug resistance in melanoma by playing a dual role: protection of tumor cells from reactive oxygen species (ROS) and DNA damage (intrinsic), and co-option of myeloid and lymphoid populations to establish immunosuppression (extrinsic).

摘要

肌球蛋白II及其调节因子Rho相关卷曲螺旋蛋白激酶（ROCK）对于细胞侵袭和转移扩散至关重要。我们最近的研究结果表明，这种分子机制在黑色素瘤的耐药性中也发挥着双重作用：保护肿瘤细胞免受活性氧（ROS）和DNA损伤（内在作用），以及利用髓系和淋巴细胞群体建立免疫抑制（外在作用）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398c/7199747/902104bac03e/kmco-07-03-1735911-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398c/7199747/902104bac03e/kmco-07-03-1735911-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398c/7199747/902104bac03e/kmco-07-03-1735911-g001.jpg

相似文献

1
What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation.那些杀不死你的，会使你变得更强大：通过细胞骨架重塑和肌球蛋白II重新激活在抗癌治疗中存活下来。
Mol Cell Oncol. 2020 Mar 26;7(3):1735911. doi: 10.1080/23723556.2020.1735911. eCollection 2020.
2
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance.肌球蛋白 II 的重新激活和细胞骨架重塑作为黑色素瘤治疗耐药性的标志和弱点。
Cancer Cell. 2020 Jan 13;37(1):85-103.e9. doi: 10.1016/j.ccell.2019.12.003.
3
Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination.细胞骨架传感器激活p53以控制DNA损伤与肿瘤播散之间的平衡
J Natl Cancer Inst. 2015 Oct 13;108(1). doi: 10.1093/jnci/djv289. Print 2016 Jan.
4
Location, location, location: Melanoma cells "living at the edge".位置，位置，还是位置：处于“边缘地带”的黑色素瘤细胞。
Exp Dermatol. 2022 Jan;31(1):82-88. doi: 10.1111/exd.14423. Epub 2021 Jul 5.
5
Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway.通过他汀类药物诱导阻断 Rho/Rho 相关卷曲螺旋蛋白激酶通路减少小鼠黑色素瘤的肺转移、细胞侵袭和黏附。
J Exp Clin Cancer Res. 2010 Sep 16;29(1):127. doi: 10.1186/1756-9966-29-127.
6
Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment.肌球蛋白 II 在癌细胞中的区域激活通过与免疫微环境的分泌串扰推动肿瘤进展。
Cell. 2019 Feb 7;176(4):757-774.e23. doi: 10.1016/j.cell.2018.12.038. Epub 2019 Jan 31.
7
Structure of a highly conserved domain of Rock1 required for Shroom-mediated regulation of cell morphology.Rock1 高度保守结构域对于 Shroom 介导的细胞形态调节的作用。
PLoS One. 2013 Dec 9;8(12):e81075. doi: 10.1371/journal.pone.0081075. eCollection 2013.
8
Inhibition of Rho-associated coiled-coil containing protein kinase enhances the activation of epidermal growth factor receptor in pancreatic cancer cells.抑制 Rho 相关卷曲螺旋蛋白激酶可增强胰腺癌细胞中表皮生长因子受体的激活。
Mol Cancer. 2011 Jul 3;10:79. doi: 10.1186/1476-4598-10-79.
9
Osteogenic differentiation regulated by Rho-kinase in periodontal ligament cells.Rho激酶调控牙周膜细胞的成骨分化
Differentiation. 2014 Sep-Oct;88(2-3):33-41. doi: 10.1016/j.diff.2014.09.002. Epub 2014 Sep 29.
10
Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II.Rho/ROCK与c-Jun氨基末端激酶之间的信号串扰介导血管紧张素II刺激的血管平滑肌细胞迁移。
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1831-6. doi: 10.1161/01.ATV.0000175749.41799.9b. Epub 2005 Jun 30.

引用本文的文献

1
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.未经治疗的转移性恶性黑色素瘤的蛋白质基因组分析
Cancers (Basel). 2025 Feb 27;17(5):832. doi: 10.3390/cancers17050832.
2
Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer.同时沉默TBCE与药物递送以克服肝癌中的铂类耐药性。
Acta Pharm Sin B. 2023 Mar;13(3):967-981. doi: 10.1016/j.apsb.2022.03.003. Epub 2022 Mar 12.
3
Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential.Rho 激酶作为癌症治疗靶点及其免疫治疗潜力。

本文引用的文献

1
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance.肌球蛋白 II 的重新激活和细胞骨架重塑作为黑色素瘤治疗耐药性的标志和弱点。
Cancer Cell. 2020 Jan 13;37(1):85-103.e9. doi: 10.1016/j.ccell.2019.12.003.
2
Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment.肌球蛋白 II 在癌细胞中的区域激活通过与免疫微环境的分泌串扰推动肿瘤进展。
Cell. 2019 Feb 7;176(4):757-774.e23. doi: 10.1016/j.cell.2018.12.038. Epub 2019 Jan 31.
3
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.
Int J Mol Sci. 2021 Nov 29;22(23):12916. doi: 10.3390/ijms222312916.
4
Delivery of Protein Kinase A by CRISPRMAX and Its Effects on Breast Cancer Stem-Like Properties.通过CRISPRMAX递送蛋白激酶A及其对乳腺癌干细胞样特性的影响。
Pharmaceutics. 2020 Dec 23;13(1):11. doi: 10.3390/pharmaceutics13010011.
多重免疫组化准确定义转移性黑色素瘤的免疫背景。
Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.
4
A Convergence-Based Framework for Cancer Drug Resistance.基于融合的癌症药物耐药性研究框架
Cancer Cell. 2018 May 14;33(5):801-815. doi: 10.1016/j.ccell.2018.03.025.
5
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.肿瘤相关巨噬细胞的PD-1表达抑制吞噬作用和肿瘤免疫。
Nature. 2017 May 25;545(7655):495-499. doi: 10.1038/nature22396. Epub 2017 May 17.
6
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
7
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.转移性黑色素瘤中抗PD-1治疗反应的基因组和转录组特征
Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17.
8
TGF-β-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination.转化生长因子-β诱导的转录维持阿米巴样黑色素瘤的迁移和播散。
Curr Biol. 2015 Nov 16;25(22):2899-914. doi: 10.1016/j.cub.2015.09.054. Epub 2015 Oct 29.
9
Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination.细胞骨架传感器激活p53以控制DNA损伤与肿瘤播散之间的平衡
J Natl Cancer Inst. 2015 Oct 13;108(1). doi: 10.1093/jnci/djv289. Print 2016 Jan.
10
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.获得MAPKi耐药性的黑色素瘤的非基因组和免疫进化
Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.